{"title":"实验室生物标志物和辛替单抗在胃癌中的免疫调节：一项肿瘤标志物和t细胞亚群的荟萃分析。","authors":"Xian Zhang, Qiang Zhao, Huafei Tang, Rui Qin, Ting Tian, Congying Li, Rui Ma","doi":"10.5937/jomb0-59513","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sintilimab, a PD-1 inhibitor, has emerged as a promising immunotherapeutic agent in gastric cancer. However, its impact on laboratory-based biochemical markers and immune indicators remains underexplored. This meta-analysis aimed to evaluate the changes in tumor biomarkers and T lymphocyte subsets, alongside clinical outcomes, in patients receiving sintilimab.</p><p><strong>Methods: </strong>A comprehensive literature search of randomized controlled trials (2022-2025) was conducted across CNKI, Wanfang, VIP, and PubMed databases. Primary outcomes included serum tumor markers (CEA, CA199, CA242) and immune parameters (CD4+, CD8+ T-cell subsets). Secondary outcomes were ORR, DCR, OS, PFS, and adverse reactions. RevMan 5.2 was used for meta-analysis.</p><p><strong>Results: </strong>Sixteen studies were included. Sintilimab treatment significantly reduced CEA, CA199, and CA242 levels (P < 0.0001), and favorably modulated immune subsets by increasing CD4+ and decreasing CD8+ cell counts. These biochemical and immunological improvements correlated with higher ORR, DCR, and OS, without increased adverse events (P > 0.05).</p><p><strong>Conclusions: </strong>Sintilimab confers measurable improvements in key laboratory-based tumor and immune biomarkers, supporting its utility in clinical biochemical monitoring and immunotherapy response evaluation for gastric cancer patients. These findings align with the emerging integration of immunotherapy and biochemical diagnostics in oncology.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 6","pages":"1171-1182"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497473/pdf/","citationCount":"0","resultStr":"{\"title\":\"Laboratory biomarkers and immunological modulation of sintilimab in gastric cancer: A meta-analysis focused on tumor markers and T-cell subsets.\",\"authors\":\"Xian Zhang, Qiang Zhao, Huafei Tang, Rui Qin, Ting Tian, Congying Li, Rui Ma\",\"doi\":\"10.5937/jomb0-59513\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Sintilimab, a PD-1 inhibitor, has emerged as a promising immunotherapeutic agent in gastric cancer. However, its impact on laboratory-based biochemical markers and immune indicators remains underexplored. This meta-analysis aimed to evaluate the changes in tumor biomarkers and T lymphocyte subsets, alongside clinical outcomes, in patients receiving sintilimab.</p><p><strong>Methods: </strong>A comprehensive literature search of randomized controlled trials (2022-2025) was conducted across CNKI, Wanfang, VIP, and PubMed databases. Primary outcomes included serum tumor markers (CEA, CA199, CA242) and immune parameters (CD4+, CD8+ T-cell subsets). Secondary outcomes were ORR, DCR, OS, PFS, and adverse reactions. RevMan 5.2 was used for meta-analysis.</p><p><strong>Results: </strong>Sixteen studies were included. Sintilimab treatment significantly reduced CEA, CA199, and CA242 levels (P < 0.0001), and favorably modulated immune subsets by increasing CD4+ and decreasing CD8+ cell counts. These biochemical and immunological improvements correlated with higher ORR, DCR, and OS, without increased adverse events (P > 0.05).</p><p><strong>Conclusions: </strong>Sintilimab confers measurable improvements in key laboratory-based tumor and immune biomarkers, supporting its utility in clinical biochemical monitoring and immunotherapy response evaluation for gastric cancer patients. These findings align with the emerging integration of immunotherapy and biochemical diagnostics in oncology.</p>\",\"PeriodicalId\":16175,\"journal\":{\"name\":\"Journal of Medical Biochemistry\",\"volume\":\"44 6\",\"pages\":\"1171-1182\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497473/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Biochemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5937/jomb0-59513\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-59513","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Laboratory biomarkers and immunological modulation of sintilimab in gastric cancer: A meta-analysis focused on tumor markers and T-cell subsets.
Background: Sintilimab, a PD-1 inhibitor, has emerged as a promising immunotherapeutic agent in gastric cancer. However, its impact on laboratory-based biochemical markers and immune indicators remains underexplored. This meta-analysis aimed to evaluate the changes in tumor biomarkers and T lymphocyte subsets, alongside clinical outcomes, in patients receiving sintilimab.
Methods: A comprehensive literature search of randomized controlled trials (2022-2025) was conducted across CNKI, Wanfang, VIP, and PubMed databases. Primary outcomes included serum tumor markers (CEA, CA199, CA242) and immune parameters (CD4+, CD8+ T-cell subsets). Secondary outcomes were ORR, DCR, OS, PFS, and adverse reactions. RevMan 5.2 was used for meta-analysis.
Results: Sixteen studies were included. Sintilimab treatment significantly reduced CEA, CA199, and CA242 levels (P < 0.0001), and favorably modulated immune subsets by increasing CD4+ and decreasing CD8+ cell counts. These biochemical and immunological improvements correlated with higher ORR, DCR, and OS, without increased adverse events (P > 0.05).
Conclusions: Sintilimab confers measurable improvements in key laboratory-based tumor and immune biomarkers, supporting its utility in clinical biochemical monitoring and immunotherapy response evaluation for gastric cancer patients. These findings align with the emerging integration of immunotherapy and biochemical diagnostics in oncology.
期刊介绍：
The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly.
The Journal publishes original scientific and specialized articles on all aspects of
clinical and medical biochemistry,
molecular medicine,
clinical hematology and coagulation,
clinical immunology and autoimmunity,
clinical microbiology,
virology,
clinical genomics and molecular biology,
genetic epidemiology,
drug measurement,
evaluation of diagnostic markers,
new reagents and laboratory equipment,
reference materials and methods,
reference values,
laboratory organization,
automation,
quality control,
clinical metrology,
all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
